Bacteriophages are viruses that infect bacteria; as such, they have many potential uses for promoting health and combating disease. This book covers the many facets of phage-bacterial-human interaction in three sections: the role and impact of phages on natural bacterial communities, the potential to develop phage-based therapeutics and other aspects in which phages can be used to combat disease, including bacterial detection, bacterial epidemiology, the tracing of fecal contamination of water and decontamination of foods.
Bacteriophages are obligate parasites that require bacterial hosts to replicate. Phages initiate infections by first attaching to the surface of bacteria and injecting their genomes into host cells. Virulent phages then hijack the host's cellular machinery to direct the production of phage virons that burst from the cell leading to bacterial lysis. In this book, the authors discuss the biology, applications and role in health and disease of bacteriophages. Topics include the varied potential roles of bacteriophages in the production of food from animal sources; phage therapy, biocontrol and commercial microbiology; abortive infection as a killer bacteriophage resistance strategy; bacteriophages as biocontrol tools of pathogens in meat and dairy products; bacteriophages as probiotics and decontaminating agents for food products; use of bacteriophages as surrogate indicators of viruses in water; promoter sequences for bacteriophage RNA polymerases; the use of bacteriophages in bacterial food pathogen regulation; and the interaction between bacteriophage and its bacterial host receptor, LamB.
This first major reference work dedicated to the mannifold industrial and medical applications of bacteriophages provides both theoretical and practical insights into the emerging field of bacteriophage biotechnology. The book introduces to bacteriophage biology, ecology and history and reviews the latest technologies and tools in bacteriophage detection, strain optimization and nanotechnology. Usage of bacteriophages in food safety, agriculture, and different therapeutic areas is discussed in detail. This book serves as essential guide for researchers in applied microbiology, biotechnology and medicine coming from both academia and industry.
An electrifying memoir of one woman's extraordinary effort to save her husband's life-and the discovery of a forgotten cure that has the potential to save millions more. "A memoir that reads like a thriller." -New York Times Book Review "A fascinating and terrifying peek into the devastating outcomes of antibiotic misuse-and what happens when standard health care falls short." -Scientific American Epidemiologist Steffanie Strathdee and her husband, psychologist Tom Patterson, were vacationing in Egypt when Tom came down with a stomach bug. What at first seemed like a case of food poisoning quickly turned critical, and by the time Tom had been transferred via emergency medevac to the world-class medical center at UC San Diego, where both he and Steffanie worked, blood work revealed why modern medicine was failing: Tom was fighting one of the most dangerous, antibiotic-resistant bacteria in the world. Frantic, Steffanie combed through research old and new and came across phage therapy: the idea that the right virus, aka "the perfect predator," can kill even the most lethal bacteria. Phage treatment had fallen out of favor almost 100 years ago, after antibiotic use went mainstream. Now, with time running out, Steffanie appealed to phage researchers all over the world for help. She found allies at the FDA, researchers from Texas A&M, and a clandestine Navy biomedical center -- and together they resurrected a forgotten cure. A nail-biting medical mystery, The Perfect Predator is a story of love and survival against all odds, and the (re)discovery of a powerful new weapon in the global superbug crisis.
Bacteriophages, or phages, are viruses that infect bacteria and are believed to be the most abundant and genetically diverse organisms on Earth. As such, their ecology is vast both in quantitative and qualitative terms. Their abundance makes an understanding of phage ecology increasingly relevant to bacterial ecosystem ecology, bacterial genomics and bacterial pathology. Abedon provides the first text on phage ecology for almost 20 years. Written by leading experts, synthesizing the three key approaches to studying phage ecology, namely studying them in natural environments (in situ), experimentally in the lab, or theoretically using mathematical or computer models. With strong emphasis on microbial population biology and distilling cutting-edge research into basic principles, this book will complement other currently available volumes. It will therefore serve as an essential resource for graduate students and researchers, particularly those with an interest in phage ecology and evolutionary biology.
This book gives a detailed yet clear insight into the current state of the art of the therapeutic application of bacteriophages in different conditions. The authors bring in their practical expertise within their respective fields of expertise and provide an excellent overview of the potential and actual use of phage therapy. Topics like economic feasibility compared to traditional antibiotics and also regulatory issues are discussed in far detail. This new volume is therefore a valuable resource for individuals engaged in the medical application of novel phage therapies.
In response to the emergence of pathogenic bacteria that cannot be treated with current antibiotics, many researchers are revisiting the use of bacteriophages, or phages, to fight multidrug-resistant bacteria. Bacteriophages: Biology and Applications provides unparalleled, comprehensive information on bacteriophages and their applications, such as phage therapy. It offers techniques, media, and methodology involved in isolating and working with therapeutic phages. Photographs, line drawings, and electron micrographs of phages are also included. With its broad approach, this book is a useful reference for microbiologists, hematologists, and infectious disease researchers.
Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.
Bacteriophages (phages) are the viruses of bacteria and biofilms that represent a frequent niche for bacteria, where they are embedded in extensive extracellular polymeric substances (EPS) and can be structured into complex microcolonies. As a consequence of the resulting spatial structure and heterogeneity, phage-bacterial interactions within biofilms can be more complicated than those between phages and planktonic bacteria. This book presents and discusses research which provides a better understanding of the biology of phages interacting with biofilms.
